Cargando…

Pediatric hereditary angioedema

Hereditary angioedema (HAE) is a lifelong illness characterized by recurrent swelling of the skin, intestinal tract, and, ominously, the upper airway. It is caused by inadequate activity of the protein C1-inhibitor, with dysfunction in the kallikrein/bradykinin pathway underlying the clinical sympto...

Descripción completa

Detalles Bibliográficos
Autor principal: MacGinnitie, Andrew J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282351/
https://www.ncbi.nlm.nih.gov/pubmed/24313851
http://dx.doi.org/10.1111/pai.12168
_version_ 1782351120392257536
author MacGinnitie, Andrew J
author_facet MacGinnitie, Andrew J
author_sort MacGinnitie, Andrew J
collection PubMed
description Hereditary angioedema (HAE) is a lifelong illness characterized by recurrent swelling of the skin, intestinal tract, and, ominously, the upper airway. It is caused by inadequate activity of the protein C1-inhibitor, with dysfunction in the kallikrein/bradykinin pathway underlying the clinical symptoms. In addition to the physical symptoms, patients experience significant decrements in vocational and school achievement as well as in overall quality of life. Symptoms often begin in childhood and occur by age 20 in most patients, but life-threatening attacks are uncommon in the pediatric population. The availability of new therapies has transformed the management of HAE.
format Online
Article
Text
id pubmed-4282351
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-42823512015-01-15 Pediatric hereditary angioedema MacGinnitie, Andrew J Pediatr Allergy Immunol Review Articles Hereditary angioedema (HAE) is a lifelong illness characterized by recurrent swelling of the skin, intestinal tract, and, ominously, the upper airway. It is caused by inadequate activity of the protein C1-inhibitor, with dysfunction in the kallikrein/bradykinin pathway underlying the clinical symptoms. In addition to the physical symptoms, patients experience significant decrements in vocational and school achievement as well as in overall quality of life. Symptoms often begin in childhood and occur by age 20 in most patients, but life-threatening attacks are uncommon in the pediatric population. The availability of new therapies has transformed the management of HAE. BlackWell Publishing Ltd 2014-08 2013-12-09 /pmc/articles/PMC4282351/ /pubmed/24313851 http://dx.doi.org/10.1111/pai.12168 Text en © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review Articles
MacGinnitie, Andrew J
Pediatric hereditary angioedema
title Pediatric hereditary angioedema
title_full Pediatric hereditary angioedema
title_fullStr Pediatric hereditary angioedema
title_full_unstemmed Pediatric hereditary angioedema
title_short Pediatric hereditary angioedema
title_sort pediatric hereditary angioedema
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282351/
https://www.ncbi.nlm.nih.gov/pubmed/24313851
http://dx.doi.org/10.1111/pai.12168
work_keys_str_mv AT macginnitieandrewj pediatrichereditaryangioedema